 |
|
Management Team
Metabolon has assembled an outstanding group of talented and experienced managers to develop and execute the business plan. We have also assembled an impressive science staff that includes specialists in biochemistry, mass spectrometry, software development and databasing. |
|
John Ryals, Ph.D., Board Member, President and Chief Executive Officer, received a Ph.D. in Molecular Biology from the University of Texas at Dallas. Prior to joining Metabolon, Dr. Ryals was CEO, President and Founder of Paradigm Genetics, Inc. (NASDAQ:PDGM). There, he raised over $100 million in equity financing, including an Initial Public Offering in 2000 and a follow on offering in 2001 and closed on R&D partnerships valued at over $200 million. Dr. Ryals has 20 years of experience in the biotechnology industry including senior research positions at Novartis and Ciba-Geigy and currently serves on the Board of North Carolina State University College of Physical and Mathematical Sciences.
|
|
S. Todd Lynch, CPA, Chief Financial Officer, is a certified public accountant with 20 years of executive and financial experience with life science companies and public accounting. Prior to joining Metabolon, Mr. Lynch was vice president, global finance for the clinical division of Inveresk, a contract research organization and subsidiary of Charles River Laboratories. Mr. Lynch also served in various financial roles for GlaxoSmithKline and gained seven years of public accounting experience with Coopers & Lybrand specializing in healthcare and manufacturing.
|
|
Michael (Mike) Milburn, Ph.D., Chief Scientific Officer, received his Ph.D. in structural chemistry at the University of California, Berkeley and was a research fellow at Harvard Medical School for his post-doctoral work. Before joining Metabolon, Dr. Milburn was senior vice president of research and corporate development at Sirtris Pharmaceuticals where he led the preclinical/clinical development of projects in the areas of metabolic disease and neurodegeneration. Prior to Sirtris, Dr. Milburn was senior vice president of research at Plexxikon, Inc., responsible for the development of Plexxikon's proprietary high-throughput cocrystallography drug discovery platform. Dr. Milburn has over 15 years of experience in biotech and pharmaceutical companies including previous positions at Structural Genomix and GlaxoSmithKline.
|
|
Tim Germann, Vice President, Sales, earned a bachelor's degree in marketing and finance from Brigham Young University and has been integral in sales, management and new product introductions at Molecular Devices, Stratagene, and Incyte Genomics. Mr. Germann comes to Metabolon most recently from U.S. Genomics where he established a sales and marketing team to launch and commercialize the Trilogy® Single Molecule Analyzer and over 300 assays. Prior to that, he was responsible for generating more than $30 million in revenue for Affymetrix where he helped to lead the Americas launch of the 10K, 100K, and 500K SNP arrays.
|
|
Don Rose, Ph.D., Vice President, Marketing received both his BS (Nutrition) and Ph.D. (Analytical Chemistry) from the University of North Carolina at Chapel Hill. He has worked in the life science tools and technology industry for over 20 years, with experience in basic research, product development, technology commercialization, and strategic marketing. Dr. Rose's experience includes senior marketing and product development positions at Hewlett-Packard, Glaxo, and Cartesian Technologies. Most recently, he led the commercial development for several life science start-ups including Phase Bioscience, Data-Centric Automation, and Deerac Fluids. |
|
|
|
|
|
